2 enrolling by invitation. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
Adenoma, Islet Cell (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Mesothelioma, Malignant (1) · Neuroendocrine Tumors (1) · Neurofibrosarcoma (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Fibrosarcoma (1)
Injections (1) · PM 01183 (1)
National Cancer Center, Korea (1) · Stella Pharma Corporation (1)
Japan (1) · South Korea (1)